查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1627937

螢光導引手術系統市場機會、成長促進因素、產業趨勢分析與預測 2024 - 2032 年

Fluorescence Guided Surgery Systems Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 - 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 145 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

2023 年，全球螢光導引手術系統市場估值達到 1.013 億美元，預計 2024 年至 2032 年複合年成長率為 14.1%。精準、更有效的手術。

政府致力於加強手術基礎設施的措施正在推動對螢光導引手術 (FGS) 系統的巨大需求。這些舉措通常涉及對先進醫療技術、設施升級以及鼓勵使用創新工具來提高手術精度和結果的投資。這筆補助支持 OnLume 開發其 FGS 系統，旨在改進該設備，以改善血管和小淋巴組織的術中可視化，最終提高手術準確性和患者效果。

市場依類型分為 VS3 Iridium 系統、SPY 系統、PDE 系統等。 2023 年，SPY 系統細分市場佔據領先地位，市場佔有率為 38.1%，預計將以 15% 的複合年成長率成長。 SPY 系統以其先進的成像和精確度而聞名，它使用 ICG 螢光成像來可視化血流和組織灌注，這對於提高手術準確性至關重要，使外科醫生能夠評估組織活力並即時做出明智的決策。

市場範圍
開始年份 2023年
預測年份 2024-2032
起始值 1.013 億美元
預測值 3.307 億美元
複合年成長率 14.1%

從應用來看，市場分為腹腔鏡/內視鏡手術和開放性手術。開放手術在 2023 年佔據最大佔有率，達到 54.2%，這主要是由於其在複雜、廣泛的手術中的作用。 FGS 系統在開放式手術中特別有用，它們可以使腫瘤和鄰近組織詳細可視化，有助於精確去除惡性細胞並最大限度地降低殘留疾病的風險。

美國在北美 FGS 市場佔據主導地位，2023 年收入為 3,840 萬美元。癌症的高盛行率進一步推動了對 FGS 的需求，因為外科醫生優先考慮可提高挑戰性手術結果的技術。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 慢性病盛行率增加
      • 癌症和心血管疾病靶向手術的成長
      • 越來越注重改善手術效果、減少手術時間
      • 旨在改善外科基礎設施的政府舉措
    • 產業陷阱與挑戰
      • 手術設備及耗材成本高
      • 螢光成像程序的報銷範圍有限
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略儀表板

第 5 章：市場估計與預測：按類型，2021 - 2032

  • 主要趨勢
  • 間諜系統
  • 光動態眼 (PDE) 系統
  • VS3銥系統
  • 其他類型

第 6 章：市場估計與預測：按手術分類，2021 - 2032 年

  • 主要趨勢
  • 開放性手術
  • 腹腔鏡/內視鏡手術

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 癌症手術
  • 心血管手術
  • 其他應用

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

  • 主要趨勢
  • 醫院和診所
  • 門診手術中心
  • 腫瘤中心
  • 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國

第 10 章：公司簡介

  • B. Braun
  • Carl Zeiss
  • Danaher Corporation
  • Getinge
  • Hamamatsu Photonics
  • Intuitive Surgical
  • KARL STORZ
  • Medtronic
  • Olympus Corporation
  • OnLume
  • Shimadzu Corporation
  • Stryker Corporation
  • Samvardhana Motherson International
  • Sumitomo Mitsui Financial Group
簡介目錄
Product Code: 9171

The Global Fluorescence Guided Surgery Systems Market reached a valuation of USD 101.3 million in 2023 and is projected to grow at a CAGR of 14.1% from 2024 to 2032. FGS systems enhance surgical procedures by providing real-time imaging that differentiates tissues with fluorescent dyes, supporting more precise and effective surgeries.

Government initiatives focused on enhancing surgical infrastructure are driving significant demand for fluorescence-guided surgery (FGS) systems. These initiatives typically involve investments in advanced medical technologies, facility upgrades, and encouraging the use of innovative tools that improve surgical precision and outcomes. The grant supports OnLume's development of its FGS system, aiming to refine the device for improved intraoperative visualization of blood vessels and small lymphatic tissues, ultimately enhancing surgical accuracy and patient results.

The market is categorized by type into VS3 Iridium systems, SPY systems, PDE systems, and others. In 2023, the SPY system segment led with a market share of 38.1% and is expected to grow at a 15% CAGR. Known for its advanced imaging and precision, the SPY system uses ICG fluorescence imaging to visualize blood flow and tissue perfusion essential for enhancing surgical accuracy by enabling surgeons to assess tissue viability and make informed decisions in real-time.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$101.3 Million
Forecast Value$330.7 Million
CAGR14.1%

In terms of application, the market is divided into laparoscopic/endoscopic surgery and open surgery. Open surgery held the largest share in 2023 at 54.2%, largely due to its role in complex, extensive procedures. FGS systems are particularly beneficial in open surgeries, where they enable detailed visualization of tumors and adjacent tissues, facilitating precise removal of malignant cells and minimizing the risk of residual disease.

The U.S. dominated the North American FGS market, generating USD 38.4 million in revenue in 2023. As a hub for medical technology innovation, the U.S. leads in growth of FGS systems with advanced imaging and new fluorescent agents. The high prevalence of cancer further drives demand for FGS, as surgeons prioritize techniques that enhance outcomes in challenging surgeries.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of chronic diseases
      • 3.2.1.2 Growth in targeted surgeries for cancer and cardiovascular disorders
      • 3.2.1.3 Growing focus towards improving surgical outcomes and reducing operating time
      • 3.2.1.4 Government initiatives aimed at improving surgical infrastructure
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of surgical equipment and consumables
      • 3.2.2.2 Limited reimbursement coverage for fluorescence imaging procedures
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 SPY system
  • 5.3 Photo Dynamic Eye (PDE) system
  • 5.4 VS3 iridium system
  • 5.5 Other types

Chapter 6 Market Estimates and Forecast, By Surgery, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Open surgery
  • 6.3 Laparoscopic/endoscopic surgery

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Cancer surgeries
  • 7.3 Cardiovascular surgeries
  • 7.4 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals and clinics
  • 8.3 Ambulatory surgery centers
  • 8.4 Oncology centers
  • 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Italy
    • 9.3.5 Spain
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 B. Braun
  • 10.2 Carl Zeiss
  • 10.3 Danaher Corporation
  • 10.4 Getinge
  • 10.5 Hamamatsu Photonics
  • 10.6 Intuitive Surgical
  • 10.7 KARL STORZ
  • 10.8 Medtronic
  • 10.9 Olympus Corporation
  • 10.10 OnLume
  • 10.11 Shimadzu Corporation
  • 10.12 Stryker Corporation
  • 10.13 Samvardhana Motherson International
  • 10.14 Sumitomo Mitsui Financial Group